{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:18:06Z","timestamp":1790191086720,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.yebeh.2020.107616","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T19:01:13Z","timestamp":1606935673000},"page":"107616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"PA","title":["The search for brain-permeant NKCC1 inhibitors for the treatment of seizures: Pharmacokinetic-pharmacodynamic modelling of NKCC1 inhibition by azosemide, torasemide, and bumetanide in mouse brain"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5391-555X","authenticated-orcid":false,"given":"Philip","family":"Hampel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"R\u00f6mermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Gramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"L\u00f6scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.yebeh.2020.107616_b0005","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrn3819","article-title":"Cation-chloride cotransporters in neuronal development, plasticity and disease","volume":"15","author":"Kaila","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"issue":"9","key":"10.1016\/j.yebeh.2020.107616_b0010","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.tins.2017.07.001","article-title":"NKCC1 chloride importer antagonists attenuate many neurological and psychiatric disorders","volume":"40","author":"Ben","year":"2017","journal-title":"Trends Neurosci."},{"issue":"9","key":"10.1016\/j.yebeh.2020.107616_b0015","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/ncpneuro0883","article-title":"Roles of the cation-chloride cotransporters in neurological disease","volume":"4","author":"Kahle","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.yebeh.2020.107616_b0020","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3389\/fnins.2019.00310","article-title":"Off-label use of bumetanide for brain disorders: an overview","volume":"13","author":"Kharod","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.yebeh.2020.107616_b0025","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neuropharm.2012.05.045","article-title":"Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments","volume":"69","author":"L\u00f6scher","year":"2013","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.yebeh.2020.107616_b0030","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/epi.12620","article-title":"Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures","volume":"55","author":"Puskarjov","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107616_b0035","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.neuropharm.2017.02.006","article-title":"Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain","volume":"117","author":"R\u00f6mermann","year":"2017","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.yebeh.2020.107616_b0040","doi-asserted-by":"crossref","first-page":"9877","DOI":"10.1038\/s41598-018-27995-w","article-title":"Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B","volume":"8","author":"Hampel","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.yebeh.2020.107616_b0045","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1074248413497257","article-title":"Diuretics: a review and update","volume":"19","author":"Roush","year":"2014","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.yebeh.2020.107616_b0050","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10545-013-9608-0","article-title":"Blood-brain barrier structure and function and the challenges for CNS drug delivery","volume":"36","author":"Abbott","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.yebeh.2020.107616_b0055","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3390\/ijms21020591","article-title":"Structural, molecular and functional alterations of the blood-brain barrier during epileptogenesis and epilepsy: a cause, consequence or both?","volume":"21","author":"L\u00f6scher","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yebeh.2020.107616_b0060","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ana.24124","article-title":"A novel prodrug-based strategy to increase effects of bumetanide in epilepsy","volume":"75","author":"T\u00f6llner","year":"2014","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.yebeh.2020.107616_b0065","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/ejn.12424","article-title":"Consequences of inhibition of bumetanide metabolism in rodents on brain penetration and effects of bumetanide in chronic models of epilepsy","volume":"39","author":"T\u00f6pfer","year":"2014","journal-title":"Eur. J. Neurosci."},{"issue":"5","key":"10.1016\/j.yebeh.2020.107616_b0070","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/epi.13346","article-title":"The bumetanide prodrug BUM5, but not bumetanide, potentiates the antiseizure effect of phenobarbital in adult epileptic mice","volume":"57","author":"Erker","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107616_b0075","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.neuropharm.2018.09.025","article-title":"Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy","volume":"143","author":"Brandt","year":"2018","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.yebeh.2020.107616_b0080","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1056-8719(97)00105-6","article-title":"Intracerebroventricular injection-induced increase in plasma corticosterone levels in the mouse: a stress model","volume":"39","author":"Kim","year":"1998","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"4","key":"10.1016\/j.yebeh.2020.107616_b0085","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0160-5402(86)90038-0","article-title":"Intracerebroventricular injections in mice. Some methodological refinements","volume":"16","author":"Laursen","year":"1986","journal-title":"J Pharmacol Methods"},{"issue":"1","key":"10.1016\/j.yebeh.2020.107616_b0090","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1602\/neurorx.2.1.73","article-title":"Active efflux across the blood-brain barrier: role of the solute carrier family","volume":"2","author":"Kusuhara","year":"2005","journal-title":"NeuroRx"},{"issue":"5","key":"10.1016\/j.yebeh.2020.107616_b0095","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/j.1476-5381.2011.01724.x","article-title":"OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies","volume":"165","author":"Roth","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.yebeh.2020.107616_b0100","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1124\/pr.113.007518","article-title":"Transporters and drug-drug interactions: important determinants of drug disposition and effects","volume":"65","author":"K\u00f6nig","year":"2013","journal-title":"Pharmacol. Rev."},{"issue":"10","key":"10.1016\/j.yebeh.2020.107616_b0105","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2174\/13816128113199990462","article-title":"Role of monocarboxylate transporters in drug delivery to the brain","volume":"20","author":"Vijay","year":"2014","journal-title":"Curr. Pharm. Des."},{"issue":"8","key":"10.1016\/j.yebeh.2020.107616_b0110","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/bdd.325","article-title":"Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery","volume":"23","author":"Kalvass","year":"2002","journal-title":"Biopharm. Drug Dispos."},{"issue":"10","key":"10.1016\/j.yebeh.2020.107616_b0115","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1002\/jps.21317","article-title":"Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding","volume":"97","author":"Waters","year":"2008","journal-title":"J. Pharm. Sci."},{"issue":"11","key":"10.1016\/j.yebeh.2020.107616_b0120","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1002\/cbdv.200900103","article-title":"Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept","volume":"6","author":"Reichel","year":"2009","journal-title":"Chem. Biodivers."},{"issue":"25","key":"10.1016\/j.yebeh.2020.107616_b0125","doi-asserted-by":"crossref","first-page":"8602","DOI":"10.1523\/JNEUROSCI.0633-10.2010","article-title":"Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy","volume":"30","author":"Brandt","year":"2010","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.yebeh.2020.107616_b0130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2174\/138920006775541525","article-title":"The role of blood-brain barrier studies in the pharmaceutical industry","volume":"7","author":"Reichel","year":"2006","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.yebeh.2020.107616_b0135","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrn1728","article-title":"Drug resistance in brain diseases and the role of drug efflux transporters","volume":"6","author":"L\u00f6scher","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"issue":"3","key":"10.1016\/j.yebeh.2020.107616_b0140","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S0022-3565(24)38041-3","article-title":"Drug-protein binding and blood-brain barrier permeability","volume":"288","author":"Tanaka","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.yebeh.2020.107616_b0145","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/bdd.2510120207","article-title":"Efficiency of different criteria for selecting pharmacokinetic multiexponential equations","volume":"12","author":"Imbimbo","year":"1991","journal-title":"Biopharm. Drug Dispos."},{"issue":"4","key":"10.1016\/j.yebeh.2020.107616_b0150","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/j.1471-4159.1993.tb13648.x","article-title":"Ionic composition of cisternal CSF in acute respiratory acidosis: lack of effect of large dose bumetanide","volume":"61","author":"Javaheri","year":"1993","journal-title":"J. Neurochem."},{"issue":"13\u201314","key":"10.1016\/j.yebeh.2020.107616_b0155","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jchromb.2011.02.018","article-title":"Sensitive isotope dilution liquid chromatography\/tandem mass spectrometry method for quantitative analysis of bumetanide in serum and brain tissue","volume":"879","author":"Li","year":"2011","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"3","key":"10.1016\/j.yebeh.2020.107616_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057148","article-title":"Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures","volume":"8","author":"Cleary","year":"2013","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.yebeh.2020.107616_b0165","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1210\/edrv-2-1-103","article-title":"Transport of protein-bound hormones into tissues in vivo","volume":"2","author":"Pardridge","year":"1981","journal-title":"Endocr. Rev."},{"issue":"4","key":"10.1016\/j.yebeh.2020.107616_b0170","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1172\/JCI110844","article-title":"Transport of propranolol and lidocaine through the rat blood-brain barrier. Primary role of globulin-bound drug","volume":"71","author":"Pardridge","year":"1983","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.yebeh.2020.107616_b0175","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S0022-3565(25)23369-9","article-title":"Differential effect of plasma protein binding of bupivacaine on its in vivo transfer into the brain and salivary gland of rats","volume":"239","author":"Terasaki","year":"1986","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.yebeh.2020.107616_b0180","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/bdd.2510160704","article-title":"Stability, tissue metabolism, tissue distribution and blood partition of azosemide","volume":"16","author":"Lee","year":"1995","journal-title":"Biopharm. Drug Dispos."},{"issue":"5","key":"10.1016\/j.yebeh.2020.107616_b0185","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/bdd.447","article-title":"Dose-independent pharmacokinetics of torasemide after intravenous and oral administration to rats","volume":"26","author":"Lee","year":"2005","journal-title":"Biopharm. Drug Dispos."},{"issue":"1","key":"10.1016\/j.yebeh.2020.107616_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bdd.693","article-title":"Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology","volume":"31","author":"VanWert","year":"2010","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.yebeh.2020.107616_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107422","article-title":"Impaired chloride homeostasis in epilepsy: molecular basis, impact on treatment, and current treatment approaches","volume":"205","author":"Auer","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.yebeh.2020.107616_b0200","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00424-013-1342-9","article-title":"Ion transporters in brain endothelial cells that contribute to formation of brain interstitial fluid","volume":"466","author":"Mokgokong","year":"2014","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.yebeh.2020.107616_b0205","first-page":"257","article-title":"Molecular mechanisms of ischemic cerebral edema: role of electroneutral ion transport","volume":"24","author":"Kahle","year":"2009","journal-title":"Physiology (Bethesda)"},{"issue":"3","key":"10.1016\/j.yebeh.2020.107616_b0210","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3171\/2009.11.JNS081052","article-title":"Molecular mechanisms of microvascular failure in central nervous system injury\u2013synergistic roles of NKCC1 and SUR1\/TRPM4","volume":"113","author":"Simard","year":"2010","journal-title":"J. Neurosurg."},{"issue":"2","key":"10.1016\/j.yebeh.2020.107616_b0215","doi-asserted-by":"crossref","first-page":"C316","DOI":"10.1152\/ajpcell.00517.2010","article-title":"Ischemia-induced stimulation of Na-K-Cl cotransport in cerebral microvascular endothelial cells involves AMP kinase","volume":"301","author":"Wallace","year":"2011","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"6","key":"10.1016\/j.yebeh.2020.107616_b0220","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1046\/j.1471-4159.1996.66062572.x","article-title":"Effect of hypoxia on Na(+)-K(+)-Cl- cotransport in cultured brain capillary endothelial cells of the rat","volume":"66","author":"Kawai","year":"1996","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.yebeh.2020.107616_b0225","doi-asserted-by":"crossref","first-page":"C88","DOI":"10.1152\/ajpcell.00148.2007","article-title":"Hypoxia effects on cell volume and ion uptake of cerebral microvascular endothelial cells","volume":"294","author":"Brillault","year":"2008","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"9","key":"10.1016\/j.yebeh.2020.107616_b0230","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/01.WCB.0000130867.32663.90","article-title":"Bumetanide inhibition of the blood-brain barrier Na-K-Cl cotransporter reduces edema formation in the rat middle cerebral artery occlusion model of stroke","volume":"24","author":"O'Donnell","year":"2004","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.yebeh.2020.107616_b0235","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuint.2017.05.020","article-title":"Inhibition of Na(+)-K(+)-2Cl(-) cotransporter attenuates blood-brain-barrier disruption in a mouse model of traumatic brain injury","volume":"111","author":"Zhang","year":"2017","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.yebeh.2020.107616_b0240","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuroscience.2014.11.031","article-title":"In vivo effects of bumetanide at brain concentrations incompatible with NKCC1 inhibition on newborn DGC structure and spontaneous EEG seizures following hypoxia-induced neonatal seizures","volume":"286","author":"Wang","year":"2015","journal-title":"Neuroscience"},{"issue":"6","key":"10.1016\/j.yebeh.2020.107616_b0245","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1089\/neu.1994.11.679","article-title":"Treatment of vasogenic brain edema with the novel Cl- transport inhibitor torasemide","volume":"11","author":"Staub","year":"1994","journal-title":"J. Neurotrauma"},{"issue":"2","key":"10.1016\/j.yebeh.2020.107616_b0250","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0031-6997(25)07319-3","article-title":"Ionization, pH and biological activity","volume":"4","author":"Albert","year":"1952","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/j.yebeh.2020.107616_b0255","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s002329900434","article-title":"Blood-brain barrier permeation: molecular parameters governing passive diffusion","volume":"165","author":"Fischer","year":"1998","journal-title":"J. Membr. Biol."},{"issue":"3","key":"10.1016\/j.yebeh.2020.107616_b0260","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1517\/17425247.3.3.419","article-title":"Drug delivery across the blood-brain barrier: why is it difficult? How to measure and improve it?","volume":"3","author":"Su","year":"2006","journal-title":"Expert Opin. Drug Deliv."},{"issue":"1","key":"10.1016\/j.yebeh.2020.107616_b0265","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s12031-007-0055-y","article-title":"The role of size and charge for blood-brain barrier permeation of drugs and fatty acids","volume":"33","author":"Seelig","year":"2007","journal-title":"J. Mol. Neurosci."},{"issue":"6","key":"10.1016\/j.yebeh.2020.107616_b0270","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/bdd.2510140609","article-title":"Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt induced hypertensive rats","volume":"14","author":"Han","year":"1993","journal-title":"Biopharm. Drug Dispos."},{"issue":"4","key":"10.1016\/j.yebeh.2020.107616_b0275","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/(SICI)1099-081X(199905)20:4<225::AID-BDD176>3.0.CO;2-E","article-title":"Gender differences in pharmacokinetics and pharmacodynamics of azosemide in rats","volume":"20","author":"Lee","year":"1999","journal-title":"Biopharm. Drug Dispos."},{"issue":"6","key":"10.1016\/j.yebeh.2020.107616_b0280","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.1986.112","article-title":"Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with chronic renal failure","volume":"39","author":"Lau","year":"1986","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.yebeh.2020.107616_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199834010-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of torasemide","volume":"34","author":"Knauf","year":"1998","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.yebeh.2020.107616_b0290","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/bdd.365","article-title":"Pharmacokinetics and pharmacodynamics of azosemide","volume":"24","author":"Suh","year":"2003","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.yebeh.2020.107616_b0295","series-title":"Goodman & Gilman's The Pharmacological Basis of Therapeutics","first-page":"671","article-title":"Regulation of renal function and vascular volume","author":"Reilly","year":"2011"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020307964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020307964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:37:17Z","timestamp":1761503837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505020307964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":59,"alternative-id":["S1525505020307964"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107616","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The search for brain-permeant NKCC1 inhibitors for the treatment of seizures: Pharmacokinetic-pharmacodynamic modelling of NKCC1 inhibition by azosemide, torasemide, and bumetanide in mouse brain","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107616","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107616"}}